Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Objective Response Rate (ORR) — 3.92 Participants (%)

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Response Rate — 0 percentage of patients responding

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Overall Survival — 13.4 month

Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months

Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants

Primary: Number of Participants With Progression at the 3 Month Follow up Visit — 15; 7 participants

Primary: Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 15.4 percentage of participants

Primary: Overall Survival (OS) — 11.96 Months

Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants

Primary: RR — 15 Participants

Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants

Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants

Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants

Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Positive…

Primary: Time to Progression — 4.50; 7.66; 5.55 Months

Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Progression-free Survival (PFS) — 5.257 months

Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants

Primary: Progression-free Survival — 4.7; 5.1 months

Primary: Progression Free Survival(PFS) — 2.6; 1.8 month

Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants

Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants

Primary: Overall Response Rate — 0.029 proportion of paticipants